Page results
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
Arif Ahmed is an entrepreneur and private equity investor in healthcare, technology, e-commerce and B2B services companies. He has a proven track record of scaling innovation in complex regulatory environments.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
This page tells you about the procedure known as varicocele (pronounced VARI-CO-SEAL) embolisation.
-
Advice on preventing the spread of flu and other respiratory viruses, to keep UCLH patients safe.
-
Introduction of Bordetella pertussis PCR testing at Halo laboratory (Health Services Laboratories)
-
This information is for patients who have been given a hinge knee brace.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
This information is for patients who have been given a walking boot, including air cast boots, pneumatic walking boots and vacoped boots.
-
This information is for patients receiving steroids for immunotherapy toxicity.
File results
-
FOI/2022/0533 - Pathology service carrying out PCR testing for SARS-CoV2
-
FOI/2022/0539 - Pharmacological choices made for patients undergoing joint replacement surgery
-
FOI/2022/0557 - Patients treated with Visudyne (verteporfin)
-
FOI/2022/0563 - Ambulatory cardiac monitoring
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0545 - Criteria used in determining acceptance of GP referrals for osteoporosis treatment, and for priorisation of osteoporosis appointments
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer